Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/ASO.2004.06.924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial.
J Radiat Oncol
December 2015
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.
Objective: The purpose of this study was to report the treatment-induced adverse events and cosmetic and treatment outcomes of accelerated partial breast irradiation (APBI) delivered with the MammoSite radiation therapy system (RTS) in breast cancer patients undergoing breast-conserving therapy (BCT).
Methods: This is a prospective clinical trial that was approved by the institutional review board. The study included female breast cancer patients undergoing breast-conserving therapy in the form of surgery and APBI delivered with the MammoSite RTS.
Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial.
Ann Surg Oncol
May 2012
Department of Radiation Oncology, Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Background: The American Society of Breast Surgeons (ASBrS) enrolled women in a registry trial to prospectively study patients treated with the MammoSite RTS device. This report presents 6-year data on treatment-related toxicities from the trial.
Methods: A total of 1449 primary early-stage breast cancers were treated with accelerated partial breast irradiation (APBI) using the MammoSite device (34 Gy in 10 fractions) in 1440 women.
Dosimetric parameters in partial breast irradiation through brachytherapy.
Med Dosim
October 2009
Department of Radiation Oncology, St. Vincent, Green Bay, WI 54301, USA.
The objective of this work is to evaluate biological models and dose homogeneity in a new partial breast irradiation method, the MammoSite RTS. The study is based on 11 patients who received the therapy. For each patient, we determined the dose volume distribution delivered to the breast.
View Article and Find Full Text PDFFactors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial.
Ann Surg Oncol
September 2009
Department of Radiation Oncology, The Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Purpose: To evaluate factors associated with optimal cosmetic results at 36 months for early-stage breast cancer patients enrolled on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy registry trial.
Materials And Methods: 1,440 patients (1,449 cases) with early-stage breast cancer undergoing breast-conserving therapy were treated with the MammoSite radiation therapy system (RTS) brachytherapy catheter to deliver adjuvant accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions).
Local control, toxicity, and cosmesis in women younger than 50 enrolled onto the American Society of Breast Surgeons MammoSite Radiation Therapy System registry trial.
Ann Surg Oncol
June 2009
Department of Radiation Oncology, Robert Wood Johnson University Hospital/Cancer Institute of New Jersey, New Brunswick, USA.
Background: The American Society of Breast Surgeons enrolled women onto a registry trial to prospectively study patients treated with the MammoSite Radiation Therapy System (RTS) breast brachytherapy device. This report examines local recurrence (LR), toxicity, and cosmesis as a function of age in women enrolled onto the trial.
Methods: A total of 1449 primary early-stage breast cancers were treated in 1440 women.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!